Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (9877)	2/20/2018 3:26:35 PM
From: drkaz	Respond to of 12873

This is actually something that many of us suspected (hoped?) the company would do, sooner or later, as one of the recurring complaints was that NNVC needed a CEO with direct experience in leading a drug/treatment through FDA review, clinical testing, and into production stages. I would have preferred that the interim CEO be one of the board members, rather than Dr. Diwan, as he's already got a lot of control in the company already. However, as long as they get somebody from the outside with experience that neither Diwan nor Seymour has - I view this as a significant plus. This information, coupled with the information that the toxicity work is done, and that there still is no observed toxicity, is very good news. We'll have to see how the market views it over the next couple of weeks.